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Abstract  
Background: Use of strongly hypofractionated radiation treatments in dogs with intracranial neoplasia did 
not improve outcomes and yielded increased rates of toxicosis.  
Hypothesis / Objective: To evaluate the safety and efficacy of a new, moderately hypofractionated 
radiation protocol of 10 x 4 Gy compared to a standard protocol.  
Animals: Convenience sample of 56 client owned dogs with primary symptomatic brain tumors. 
Methods: Retrospective observational study. Twenty-six dogs were assigned to the control standard 
protocol of 20 x 2.5 Gy (group A), 30 dogs to the new protocol of 10 x 4 Gy (group B). Protocols were 
assigned on owners’ informed consent. Statistical analysis was conducted under the "as treated" regime, 
using Kaplan-Meier and Cox-regression analysis. Treatment was delivered with technically advanced 
image-guided radiation therapy. The two treatment groups were compared in terms of outcome and signs 
of toxicosis.  
Results: Overall progression-free interval (PFI) and overall survival time (OS) were favorable, with 663 
(95%CI: 497;828), and 637 (95%CI: 403;870) days respectively. We found no significant difference 
between the two groups: PFI for dogs in group A vs. B was 608 (95%CI: 437;779) days and mean 
(median not reached) 863 (95%CI: 644;1083) days, respectively (p=0.89), and OS for dogs in group A vs. 
B 610 (95%CI: 404;816) and mean (median not reached) 796 (95%CI: 586;1007) days (p=0.83). 
Radiation toxicosis was suspected in 2 cases. 
Conclusion and clinical importance: In conclusion, 10x4 Gy is a safe and efficient protocol for treatment 
of primary intracranial neoplasia and future dose escalation can be considered.  
	 4 
Introduction  
Definitive-intent radiation therapy for dogs with intracranial tumors provides a long-term tumor control 
with a reasonably low risk of late complications. In general, best survival outcomes involve radiation 
protocols with relatively small fractions sizes of 2-3 Gy in 18-22 fractions, to total doses of 45-54 Gy.1-3 
With such protocols, outcome has been attributed to be dependent on tumor size, but surprisingly neither 
to location or presumed known tumor type.1-3  
Attempts to shorten radiation protocols for intracranial tumors in dogs by reducing fraction number 
drastically, while maintaining an adequate total dose have been made but hypofractionated treatments 
have not reached the same outcomes with median survival times of only 1-1.5 years4, compared to >2 
years with more finely fractionated protocols.1-3 Moreover, dogs treated with more coarsely fractionated 
protocols (and often lower total doses) have increase in toxicoses and impaired quality of life, especially 
when treated with older techniques.5-8 Ideally, such a change in protocol maintains a similar efficacy with 
no observable or only a slight increase in risk for toxicosis. Late radiation toxicosis in the brain remains 
difficult to detect with no consensus in medical literature as to which criteria should be used. Diagnostic 
imaging after recurrence of signs of neurologic disease provides some information as to whether 
worsening is due to tumor progression or late radiation toxicosis.9-11 Conventional diagnostic imaging 
modalities fail to reliably differentiate active neoplastic tissue from radiation necrosis.9,12   
In radiation therapy, the risk of toxicosis can be anticipated. In a prior study we calculated the normal 
tissue complication probability (NTCP) with clinical data of former dogs with brain tumor with 10x4.35 
Gy to be safe with a low risk of radiation-induced toxicosis for most tumor sizes and locations, given an 
appropriate technical radiation therapy standard. This protocol provides the same biologically effective 
dose (BED) as the routinely used 20x2.5 Gy protocol, and should theoretically result in an equal tumor 
control.13  
However, in order to implement such a new, moderately hypofractionated, 10-fraction protocol into 
clinical practice, we used a conservative approach: instead of using 10x4.35 Gy, we started with a lower-
dose protocol of 10x4 Gy. This protocol was calculated for having the “same risk” (probability estimates 
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of late toxicosis, e.g. NTCP) and hence a lower biologically effective dose (BED). As a consequence, the 
10x4 Gy protocol was expected to have a clinically detectable inferior outcome.   
The aim of this clinical study was to provide data on clinical outcome described as progression-free 
interval and overall survival, as well as clinical performance and the occurrence of adverse events in dogs 
with intracranial tumors irradiated with either 10x4 Gy or the traditional protocol of 20x2.5 Gy. We 
hypothesized that a clinically detectable difference of outcome for progression-free interval, overall 
survival time or both between the two treatment groups should occur, due to differences in the BED given. 
The resulting data will be used for the future decision, whether clinical escalation of dose per fraction for 
the irradiation in 10 fractions can be safely attempted.  
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Material and Methods:  
Study design 
Retrospective observational study. 
 
Dog and tumor characteristics 
Client-owned dogs diagnosed with symptomatic primary intracranial tumors presented for radiotherapy at 
the Division of Radiation Oncology, Vetsuisse Faculty, University Zurich, Switzerland were enrolled in 
the study. The intracranial tumors were diagnosed based on neurologic examination including examination 
of cerebrospinal fluid (CSF) and magnet resonance imaging (MRI) or computed tomography (CT).10,11,14-17 
Clinical data including signalment, tumor type based on diagnostic imaging, tumor size and location, 
staging work-up, treatment modality, treatment schedule and response, time to last follow up, time to 
progression, time to death and cause of death, was collected. All symptomatic primary intracranial tumors 
were enrolled, including pituitary tumors and no difference was made in terms of workup and treatment 
recommendations. Workup included clinical and neurological examination, complete blood count (CBC), 
biochemical profile, thoracic radiographs or CT and further exams such as CSF analysis, if indicated for 
the specific findings. Dogs with signs of neurologic disease at presentation were categorized into showing 
mild, moderate or severe signs.3 Seizures as a neurologic abnormality were recorded separately since they 
were not included in this classification system. 
 
Treatment  
Protocol choice was left to owner’s decision and made by owner’s informed verbal or signed consent. 
Dogs were treated with either 20x2.5 Gy (group A) or 10x4 Gy (group B). However, most dogs before 
2015 were treated with a 20-fraction protocol and the switch to more 10-fraction treatments was made in 
May 2015. As similar protocols have been published in the past and a risk estimate existed7,13, no formal 
ethics approval from the Animal Ethics Council of the Canton of Zurich, Switzerland was needed.  
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Radiation was delivered with a 6MV linear acceleratora equipped with a 5mm leaf-width multi-leaf-
collimator, using photons and 3-dimensional conformal radiation therapy (3DCRT) or intensity-modulated 
radiation therapy (IMRT). 
Treatment planning was performed using Eclipse External Beam planning softwareb, applying 
AAA-algorithm (10.0.28). Radiation was planned isocentrically, with heterogeneity correction, by a 
board-certified radiation oncologist (CRB or VM). Planning-CT and daily treatments were performed 
under general anesthesia in sternal recumbency. Reproducible positioning was accomplished with both an 
individually shaped vacuum cushionc and a custom-made bite block.18 Target volumes and organs at risk 
(OAR) were contoured in a facility internal standardized manner as previously published by our research 
team.13 In brief, the gross tumor volume (GTV) was delineated using co-registered contrast-enhanced CT 
images or CT and MRI images, in tumors with no contrast uptake T2 sequences were used for delineation 
of GTV. Clinical target volume (CTV), accounting for subclinical microscopic disease extension of 2-8 
mm (presumed local infiltration, according to tumor type) was defined. The CTV-margin was then 
extended three-dimensionally by 2 mm to define the planning target volume (PTV), accounting for setup 
uncertainties in daily image-guided photon treatment. OAR were segmented as described previously.13 
Additionally, for the assessment of radiation toxicosis, a volume PTVbrain was computed, representing the 
portion of the PTV inside the calvarium. Furthermore, the ratio of the target volume to the entire brain 
volume (BV) was computed for each target volume. Accuracy of positioning in daily treatments was 
provided with on-board imaging (OBI) and daily orthogonal kilovolt (kV)-images. The recommendations 
for specifying dose and volumes were adhered to as proposed by Keyerleber et al.19, and in the ICRU 
reports 50 and 62 for 3DCRT and ICRU report 83 for IMRT plans.20-22 The dose was prescribed at the 
ICRU reference point, delivered in a protocol of either 10x4 Gy (40 Gy total dose) or 20x2.5 Gy (50 Gy 
total dose). According to the Swiss law and routine procedure in our clinic, a medical physicist approved 
all treatment plans and the IMRT treatment plans were dosimetrically verified prior to treatment using a 
phantomd.  
Treatment was delivered with definitive-intent, on a Monday to Friday schedule. 
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Additional medical treatment before and after radiotherapy was not standardized and adapted to the 
individual needs of the dogs. Medication was usually started at the day of diagnosis or beginning of signs 
of neurologic disease and adapted according to the improvement clinical signs and consisted mostly of 
antiepileptic drugs and corticosteroids.  
 
Follow up 
Dogs were invited for a clinical/neurologic examination 3 weeks after radiotherapy to check for acute 
adverse effects and re-evaluation of initial clinical and neurological abnormalities. Follow up 
examinations were recommended every 3 months for the first year after irradiation, the interval was then 
prolonged to every 6 months. Dogs underwent clinical and neurologic examination by a board-certified 
neurologist or an experienced resident in veterinary neurology. Diagnostic MRI was recommended at 6 
and 12 months after irradiation. Further diagnostics, e.g. CBC, serum biochemistry, urinalysis, thoracic 
radiographs and ultrasonography examinations were not performed routinely but based on the clinician’s 
recommendations. Suspected acute, early delayed and late radiation toxicosis was based on the VRTOG 
toxicity criteria and assessed on consensus between a board-certified radiation oncologist (CRB, VM), 
neurologist and radiologist.23 Suspected progressive disease was based on clinical and neurological 
evaluation of the dog and also assessed on consensus between a board-certified radiation oncologist (CRB, 
VM), neurologist and radiologist. In dogs with suspected progressive disease diagnostic imaging was 
recommended to confirm progressive disease. 
Diagnostic imaging was mostly performed in-house in the Clinic of Diagnostic Imaging, Vetsuisse 
Faculty, University of Zurich, or at the referring veterinarian’s diagnostic imaging institute of choice.  
Settings for diagnostic imaging performed at external facilities were not standardized. Information for 
radiologic evaluation of dogs was obtained from the original radiology report. In cases where the 
radiology report did not contain all necessary information, a board-certified radiologist (RD) reviewed all 
imaging studies of the corresponding dog. Two-dimensional tumor measurements were obtained in 
OsiriXe. For 3-dimensional tumor measurement, the control MRI studies were imported into Eclipse 
External Beam planning software, contoured and the resulting tumor volumes were derived. For dogs that 
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underwent follow-up imaging, response to treatment was assessed according to the response criteria as 
proposed by MacDonald.24  
 
Statistical analysis 
Data were coded in excel and analyzed with SPSSf. Descriptive statistics such as absolute and relative 
frequencies as well as mean (median) and standard deviation (IQR) were computed. The non-parametric 
Mann-Whitney test investigated differences in continuous variables with respect to a binary factor. The 
Chi2 test was used to disclose associations between two discrete variables. In case of death clearly due to 
other cause (without signs of disease progression), the dogs were censored at the time of death for PFI 
analysis. Median survival time (OS) was defined as the interval between the first radiation therapy until 
death. For OS, all deaths were considered events and dogs that were still alive at the time of data 
evaluation or lost to follow-up were censored. Both overall survival time and progression-free interval 
were coded and analyzed with Kaplan-Meier accompanied by the log-rank and Tarone-Ware tests and 
Cox-Regression (HR). Survival estimates and median survival time were complemented with the 
corresponding 95% confidence intervals (95%CI). If not otherwise indicated, the statistical analysis was 
conducted under the "as treated" regime. In order to adjust the statistical analysis of most important 
outcomes for the non-randomized study design the "intention-to-treat" and "per-protocol" regimes were 
applied assuming a cut-off in May 2015 (group A=treated before cut-off, group B=treated after cut-off). 
Results of statistical analyses with p-value <0.05 were considered statistically significant. 
 
Results  
Dog and tumor characteristics 
Of the 67 dogs presented for radiation therapy to the authors' institution in the relevant period between 
January 2012 and June 2017, 56 dogs (84%) met the inclusion criteria for the study: 30 were male (19 
neutered) and 26 were female (19 spayed). A total of 35 pure (n=24) and mixed (n=11) breeds were 
represented, the most common being Boxer (n=6), Golden Retriever (n=5) and Labrador Retriever (n=4). 
Age ranged from 1.5-14 years with a mean of 9.0 (± 2.9) years and weight ranged from 2.9-41.7 kg with a 
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mean of 21.0 (± 11.8) kg. Dogs with signs of neurologic disease at the time of presentation were judged as 
exhibiting mild (n=27), moderate (n=20) or severe signs (n=9). Twenty-four dogs were presented with a 
history of seizure and 11/24 dogs showed seizure as their only sign of neurologic disease. Tumors were 
radiologically diagnosed as meningioma (n=31, group A=17, group B=14), glioma (n=12, group A=6, 
group B=6), pituitary gland tumor (n=10, group A=1, group B=9), peripheral nerve sheath tumor (PNST) 
(n=2, group A only) and choroid plexus tumor (n=1, group B only). Distribution of tumor types was 
significantly different between the groups when comparing all tumor types (p=0.021). The analysis was 
repeated with tumor types occurring in both treatment groups only, however, group distribution was still 
different (p=0.028). Mean GTV was 2.76 cm3 (95%CI: 2.17;3.34) corresponding to a mean GTV/BV-ratio 
of 3.32% (95%CI: 2.60;4.03). Mean CTV was 5.67 cm3 (95%CI: 4.40;6.54) corresponding to a mean a 
CTV/BV-ratio of 6.54% (95%CI: 5.26;7.83). Mean PTVbrain was 7.01 cm3 (95%CI: 5.80;8.23) 
corresponding to a mean PTVbrain/BV-ratio of 8.47% (95%CI: 6.93;10.00). A significant difference in 
sizes between the two treatment groups was noted only in CTV (p=0.010) but not in CTV/BV-ratio or any 
other target volume characteristics. Twenty-seven tumors were located in the rostral cranial fossa, 19 in 
the middle fossa and 10 in the caudal fossa and there was no significant difference between the two 
treatment groups. In 9 dogs only CT images were available for diagnosis and delineation of target volumes 
and OAR. Of these dogs, 4/9 (44%) were diagnosed with meningioma, 1/9 (11%) with a glioma and 4/9 
(44%) with pituitary gland tumors. 
Three dogs had a surgical biopsy / debulking surgery prior to radiotherapy, all three dogs were diagnosed 
with a meningioma and surgery (leaving macroscopic tumor behind) was performed 23, 29 and 70 days 
before radiotherapy.  
 
Treatment 
Of the fifty-six dogs, 26 (46%) were treated with 20x2.5 Gy (group A), 20/26 (77%) were treated before 
the cutoff of May 2015, 6/26 (23%) were treated thereafter and 30 (54%) were treated with 10x4 Gy 
(group B), 2/30 (7%) were treated before the cutoff of May 2015, 28/30 (93%) were treated thereafter. 
Forty of 56 dogs (71%) were treated with a conformal photon plan (3DCRT), and 16/56 (29%) with an 
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intensity-modulated radiation therapy plan (IMRT, sliding window). A median of 3 fields was used (range 
2-5, 2-4 for 3D-CRT, 5 for IMRT). Of all treated dogs, 43/56 (77%) received corticosteroids at the first 
fraction with the mean dose being 0.70 mg/kg (95%CI: 0.62;0.78). Corticosteroids were reduced in 84% 
(36/43) dogs during radiotherapy by a mean of 54% (95%CI: 47;62) and could be stopped in 10 dogs after 
3 weeks, in 7 dogs after 3 months, in 7 dogs after 6 months, in 1 dog after 9 months and in 1 dog after 12 
months, 13/56 (23%) dogs did not receive corticosteroids. In 1 dog, steroid dose had to be increased 
during radiation therapy due to insufficient improvement of signs of neurologic disease. Corticosteroid 
doses and dose reductions were not significantly different between the two treatment groups. Twenty-
seven of the dogs (48%) received antiepileptic treatment consisting of either phenobarbital (n=18) in a 
dose range of 1.4 – 3.1 mg/kg BID with a mean of 2.28 mg/kg (95%CI: 2.02;2.56) or levetiracetam (n=8) 
in a dose range of 13.2 - 33 mg/kg TID with a mean of 21.25 mg/kg (95%CI: 17.23;25.27). In general, 
phenobarbital dose was titrated to the upper level of the recommended range (25-30 mg/L)25 and 
levetiracetam was added if seizure control was not complete, or if dogs had adverse effects from 
phenobarbital. Thirty-four dogs (61%) received other supportive medication as follows: gastric acid 
inhibitors (n=14), anti-emetics (n=6), antibiotics (n=9), pain killers (n=3), anti-arrhythmic drugs (n=2), 
levothyroxine (n=2) diphenhydramine (n=1), oclacitinib (n=1), different topical eye medication (n=9). 
Acute radiation toxicosis was assessed in all 56 dogs, 54/56 dogs (96%) were assessed for early delayed 
and 47/56 dogs (84%) for late radiation toxicosis. The dogs not assessed for early delayed or late radiation 
toxicosis did not live long enough for assessment. None of the dogs showed acute radiation toxicosis. In 
one dog each (1/54, 1.9% and 1/47, 2.1%) early delayed (steroid responsive and self-limiting) and late 
radiation toxicosis was suspected. 
 
Follow up and outcome  
Clinical and neurological response at six months after radiotherapy was assessed in 45/56 cases (80%; 
21/26 from group A and 24/30 from group B) and not significantly different between the groups (p=0.67): 
In group A, 19/21 showed improvement in clinical and neurological response and in group B an 
improvement in clinical and neurological response was documented in 20/24 dogs. The other 11 dogs 
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(20%) had died before they reached six months follow up (5/11 from group A and 6/11 from group B). Of 
these 11 dogs, death was attributed to the brain tumor in 10 cases, 1/11 dogs (group A) died of tumor 
unrelated causes. Of the dogs that died before they reached 6 months follow up, 4/11 showed 
improvement of signs of neurologic disease by the first control examination after radiotherapy, 5/11 
showed stable signs of neurologic disease and only 2/11 did not show improvement of signs of neurologic 
disease. Eight dogs in group A and five dogs in group B had seizures as their only presenting sign. 7/8 
dogs (88%) in group A and 4/5 (80%) in group B had improved seizure control with no or only sporadic 
(< 1/month) seizures after therapy, but it is not possible to determine, whether seizure control was due to 
tumor reduction or anti-epileptic medication.  
A total of 23 diagnostic imaging control examinations from 19 dogs were available for assessment 
according to the MacDonald response criteria.24 Fifteen studies were performed up to 6 months (mean 163 
days; ±47.9 days, range 86-219 days), 6 around the recommended 1 year (mean 363 days; ±96.9 days, 
range 236-496 days) and 2 at a later time point (538 and 895 days). Response to treatment classified 
according to the MacDonalds response criteria was complete remission (CR) in 2/23, partial remission 
(PR) in 7/23, stable disease (SD) in 10/23 and progressive disease (PD) in 4/23. Median reduction in sum-
product of longest diameters (SPD) was 35% (95%CI: 28;61). Median volumetric tumor reduction was 
43% (95%CI: 37;67). The differences in two- and three-dimensional tumor reductions were not significant 
between group A and B (p=0.56 for 2D, p=0.88 for 3D-reductions).  
Two dogs with suspected glioma had to be excluded from comparison of 2D and 3D measurements, 
because of a lack of contrast uptake of the brain lesion. 
The mean follow up was at 491 days, median at 483 days (95% CI: 281;686 days). During this time, 27 
dogs were clinically classified as progressive. The median PFI for all cases was 663 days (95%CI: 
497;828). We found no significant difference between the two groups: PFI for dogs in group A vs. group 
B was 608 (95%CI: 437;779) days and mean (median not reached) 863 (95%CI: 644;1083) days 
respectively (p=0.89). The proportion of dogs free of progression at 1- and 2-years were 83% (95%CI: 
67;99) and 34% (95%CI: 14;54) for group A and 80% (95%CI: 66;94) and 60% (95%CI: 34;86) for group 
B (Figure 1). Tumor type was a significant factor for outcome occurring in both groups (p=0.001) and 
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direct comparison revealed significantly shorter PFI for gliomas compared to meningiomas (p<0.001) with 
224 days (95%CI: 0;548) and 882 days (95%CI: 589;1175), respectively (Figure 2). Hence, for tumors 
radiologically diagnosed as gliomas, PFI was 658 days shorter (95%CI: 257;1059) than for meningiomas. 
Also, dogs with severe signs of neurologic disease had a significantly shorter PFI than dogs with mild 
signs (p=0.008): PFI was 286 days shorter (95%CI: -107;679) in cases with severe signs of neurologic 
disease compared to mild signs.  
Median OS was 637 days (95%CI: 403;870), (Figure 3). OS in group A was 610 days (95%CI: 404;816) 
and was not reached in group B, (mean OS 796 (95%CI: 585-1007) days), (p=0.83). The proportion of 
dogs alive at 1- and 2-years was 77% (95%CI: 61;93) and 45% (95%CI: 25;65) for group A, and 63% 
(95%CI: 43;83) and 57% (95%CI: 37;77) for group B. Tumor type as well as tumor and treatment 
volumes in relation to the brain volume were significant prognostic factors for survival. Median survival 
time was significantly shorter (p<0.001) for dogs with radiological diagnosis of glioma than meningioma, 
with 226 days (95%CI: 109;343) and 811 days (95%CI: 694;928). Also concerning survival time, tumors 
radiologically diagnosed as gliomas had a 585 days shorter OS (95%CI: 336;833) than tumors diagnosed 
as meningiomas. 
Of the 33 animals (59%) documented to have died, 22/26 dogs were from group A, and 12/30 dogs were 
from group B. 22/33 (67%) died of tumor (or potentially treatment) related causes, all of them showed 
worsening signs of neurologic disease and progression of clinical signs identical to the initial presentation. 
Of these dogs, 11/22 (50%) did not have imaging confirmation, therefore, late radiation toxicosis could 
not be entirely ruled out but seemed unlikely based on the clinical assessment. Death of tumor unrelated 
causes occurred in 11/33 cases (33%), these animals died of development of other neoplastic diseases 
(n=5), multi-organ failure (n=4), other not tumor related neurologic conditions (n=2).  
Survival analysis and analysis of PFI for the groups split by “intention to treat” and “per protocol” did not 
show any relevant differences to the analyses above for groups split by “as treated” factor. 
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Discussion  
In this study we chose a conservative approach for the first-time application of this moderately 
hypofractionated 10-fraction protocol in dogs. A short protocol with 10 fractions and the same risk for late 
toxicosis (NTCP), based on mathematical calculations, was compared to the standard 20-fraction 
protocol.13 Based on VRTOG clinical observations, no increased occurrence of toxicosis was found. The 
outcome, as well as the low occurrence of adverse events in dogs irradiated with this moderately 
hypofractionated protocol of 10x4 Gy for their brain tumors was not different from the standard protocol 
and can be summarized as favorable.  
Prior protocols used for the treatment of intracranial tumors in dogs using a lower fraction number 
raised the suspicion that overall survival was compromised by fatal acute or late radiation complications in 
>16%.5,8 Overall, large fraction sizes chosen and applied with older 2D or non-image guided 3D-
techniques cannot be recommended for safe future use.6 For some tumor constellations with small tumor 
volumes in non-sensitive areas, a reduction in fraction size can safely be performed, given an appropriate 
technical radiation therapy standard.4,26 Furthermore, a new protocol with 10 fractions of 4.35 Gy has been 
theoretically calculated in 64 dogs and suggested that it may be safe to treat small to intermediate sized 
tumors that are neither located near the optic chiasm nor at the brainstem with 10 daily fractions of 4.35 
Gy.13 
In the dogs that had imaging performed at progression of signs of neurologic disease, these signs 
could be attributed to tumor progression (local or locoregional) and based on diagnostic imaging, no late 
radiation toxicosis was suspected. As the latency to occurrence of radiation necrosis varies greatly, the low 
incidence might have been attributed to the only intermediate overall survival of the dogs compared to 
toxicosis outcomes observed in human patients. However, the incidence as well as the time of occurrence 
of radiation necrosis increases with increasing biologically effective dose (BED).27 The incidence of 
radiation necrosis in the cerebrum is 4% for a BED >85-120 Gy2 and increases to 17% for BED >155-190 
Gy2 and 22% for BED >190-225 Gy2.27 Calculation of BED for the protocols used in our study were on 
the lower end with 112.5 Gy2 in group A and 120 Gy2 in group B, reassuring the incidence of radiation 
necrosis is probably ≤4%, but might occur in some cases.  
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Clinical improvement as well as PFI and OS was not significantly different between the treatment 
groups, even if the lower BED in the 10-fraction protocol implies a lower efficacy and tumor control 
probability.13 The median PFI of 22 months (95%CI: 16;27) in this study as well as the percentage of dogs 
free of progression at 1- and 2-years (81% and 41%) are comparable with other studies, as their 1- and 2-
year proportions free of progression lie within our 95%CI range. Also, the overall survival with a median 
of 21 months in this study (95%CI: 13;29) and the proportion alive at 1- and 2-years (70% and 47%), 
respectively, is comparable to reported findings.1-3 The outcomes with the new, 10-fraction protocol 
represent a novelty, because the relatively lower total dose of this moderately hypofractionated protocol 
can most likely safely be escalated (as well as the total dose of a protocol with the more finely 
fractionated, 20x2.5 Gy fractions) if applied with conformal, daily image-guided therapy.  
The herein used moderately hypofractionated protocol differs from the currently increasingly used 
extreme hypofractionated stereotactic or radiosurgery treatments.4,26,28 These treatments are applied in 
humans in situations of non-infiltrative tumors and volumes that do not exceed defined sizes. The risk for 
complications in radiosurgery increases rapidly when >5-10 cm3 of brain tissue receive >12 Gy.29 In 
relation, 10 cm3 represent 0.7% of the human brain volume with an estimate of 1’400 cm3. Animals with 
brain tumors usually do not meet the criteria of non-invasiveness and small size, in our study all of the 
dogs were treated with a PTV > 2.17% of the dog’s brain volume. Consequently, such extreme treatment 
protocols are feasible in only few, carefully selected dogs in veterinary medicine. Volume 
recommendations for high doses per fraction in veterinary medicine suggest a volume for normal brain 
tissue at prescribed dose <1.1cm3 (corresponding about 1.26% under the assumption of a median brain 
volume of 87.24cm3 as commonly found in dogs), in dogs treated with 3x8 Gy, to be safe in regards of 
complications to radiotherapy.4 However, the high occurrence of locally invasive variants of meningioma, 
as well as the lack of confirmatory biopsy verifying non-invasive nature of the tumors limits the 
appropriate use of extremely hypofractionated, stereotactic radiation therapy to small - intermediate size 
benign trigeminal nerve sheath tumors and (small) pituitary adenomas. 
MRI control examinations showed marked regression of tumor volume of 19-100 % at the primary 
irradiated site in all dogs. Reduction of tumor burden depended on the method of measurement. Three-
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dimensional measurements resulted in a “greater reduction” of tumor volume than comparing the sum 
product of largest diameters. This effect occurs in human glioblastoma multiforme, suggesting three-
dimensional measurements to be preferred for accurate response assessment after radiotherapy.30,31 
Furthermore, two dogs with suspected glioma had to be excluded from comparison of 2D and 3D 
measurements, because of a lack of contrast uptake of the brain lesion. MacDonald’s response criteria 
were published in 1990 for assessment of CT studies limiting their use in MRI, which has since 
progressed to be modality of choice in brain diagnostics. 
We acknowledge the limitations of the results presented herein: The first statistical limitation was the 
almost-randomized design of the study impedes interpretation of the results. For statistical analysis, the 
"as treated" regime was applied. In this regime the dogs are assigned to the actual treatment groups. The 
chronological switch from one protocol (group A) to another (group B) does not represent an 
approximation to randomization. Therefore, two additional "intention to treat" and "per protocol" regimes 
for statistical analysis aimed at adjusting for this difficulty. The "intention to treat" regime adjusts for the 
time cut-off by allocating the dogs treated before the cut-off to the A and otherwise to the B group 
independently of their actual treatment. In contrast, the "per protocol" regime considers only dogs treated 
prior to the cut-off as truly A-dogs and those treated after the cut-off as truly B-dogs. Although, some 
dogs before May 2015 had been treated with 10x4 Gy and some dogs after May 2015 were treated with 
20x2.5 Gy, comparison of survival analysis for “as treated” with “intention to treat” and “per protocol” 
regimes showed only minor discrepancy. However, under the assumption of "same risk" (probability 
estimates of toxicosis, e.g. NTCP), one had to assume less tumor control and hence we had to leave the 
choice of protocol to the owners. The second statistical limitation was the relatively small sample size 
could limit power of statistical analyses, especially in the low frequency of occurrence of expected late 
toxicosis and survival analysis. The third statistical limitation has a large impact on the structure of 
statistical models. Due to the sample size, adjusting for possible confounders was hardly possible and only 
univariate models were considered. 
A further limitation of the study was the absence of histological confirmation of the origin of the tumor in 
the majority of the dogs. Diagnostic imaging represents a well-established modality for tumor diagnosis. 
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Intracranial neoplasia can quite reliably be differentiated from non-neoplastic diseases.10,11,14-17 
Nevertheless, accuracy for distinction between different tumor types with standard magnetic resonance 
imaging dropped to 70% in one study, making it difficult to rely on statistical differences between tumor 
types when no histology is available.16 In addition the presumed tumor types were not evenly distributed 
between the two groups, causing a possible bias. Some authors have hypothesized that pituitary tumors 
treated with radiation have a more favorable outcome compared to tumors of different histologic origin. 
The assumption that any of the possible histotypes in dogs with intracranial tumors and having resulting 
signs of neurologic disease have a different outcome upon treatment has not been shown to date.1-3,8,32 In 
our study we showed a significantly inferior outcome in terms of PFI for dogs with diagnosed glial tumors 
compared to meningioma (p=0.001), but no superior outcome for pituitary gland tumors. Another finding 
was the shorter PFI for dogs with severe signs of neurologic disease (p=0.005), which had not been shown 
in similar reports.1-3  
A further limitation of the study results from challenges encountered in measuring tumor size on CT and 
MRI in two cases. One, comparing an MRI and a CT where the high concentration of fluid surrounding 
the tumor made the interpretation of the measurements difficult, the other showing stable tumor volume in 
a dog with stable signs of neurologic disease where we therefore assumed radiation to have had a positive 
effect. 
In conclusion, the outcome, as well as the low occurrence of adverse events in dogs irradiated 
with this moderately hypofractionated protocol of 10x4 Gy for their brain tumors can be summarized as 
favorable. This shorter and hence less cost intense protocol provided an improved or even normal quality 
of life to the vast majority of dogs for a remarkable time span. When escalating the doses with this 
moderately hypofractionated protocol as a future route to improve local tumor control, correct positioning 
of the dogs and correct target localization with image-guidance as well as uniform delineation of organs at 
risk and target volumes must continuously be adhered to. In parallel to local control, potential late 
toxicoses resulting from lesser-fractioned protocols must also remain an important focus for the future.  
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Figure legends 
 
Figure 1: Proportion free of progression for the two treatment groups (black line: 10x4Gy, n=30; grey line: 
20x2.5Gy, n=26). Censor marks: In case of death clearly due to other cause (without signs of disease 
progression), the dogs were censored at the time of death for PFI analysis. The dotted lines mark 1-year 
and 2-years. No significant difference between the two groups was found (p=0.860). 
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Figure 2: Proportion free of progression for dogs with meningiomas (black line, n=31) and gliomas (grey 
line, n=12), imaging diagnosis. Censor marks: In case of death clearly due to other cause (without signs of 
disease progression), the dogs were censored at the time of death for PFI analysis. The dotted lines mark 
1-year and 2-years. PFI was significantly shorter for dogs diagnosed with gliomas (p<0.001). 
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Figure 3: Proportion alive for all dogs. Censor marks: For OS, all deaths were considered events and dogs 
that were still alive at the time of data evaluation or lost to follow-up were censored. The dotted lines 
mark 1-year and 2-years.  
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